Veteran biotechnologist Janne Kerovuo will drive technical operations, R&D for fast-growing biology engineering company
CHICAGO, Sept. 20, 2022 /PRNewswire/ -- Evozyne today announced Janne Kerovuo, PhD, as its senior vice president of research and development, a newly created position at the Chicago-based biology engineering company.
Evozyne selects veteran biotechnologist Janne Kerovuo, PhD, to lead research and development
Founded by Paragon Biosciences in 2020, Evozyne creates novel proteins for therapeutics and sustainability solutions. Evozyne is developing technology platforms for gene optimization, antibody discovery, gene editing, carbon capture and battery technology.
Kerovuo was most recently chief science officer for California-based MycoWorks and has held a variety of leadership positions with companies including NewLeaf Symbiotics, Monsanto and Agradis during his 27-year career in biotech. He holds a PhD in biochemistry from the University of Helsinki.
"The most exciting parts of my scientific career have been in enzyme and gene discovery and protein design. I strongly believe that the Evozyne approach, using evolution-based design, represents the best opportunity to unlock transformational solutions," Kerovuo said. "I look forward to meaningfully advancing the science to address some of the world's most urgent needs."
Evozyne applies boundary-breaking biology that combines engineering and AI to develop transformative solutions in biotechnology and sustainability. Built by Paragon Biosciences, Evozyne created one of the most promising technologies to improve human life. By amplifying a protein's function based on the rules of nature, Evozyne addresses complex, high-impact problems. For more information, visit https://www.evozyne.com/.
About Paragon Biosciences, LLC
Paragon Biosciences is a global life science leader that creates and builds innovative biology-based companies in three key areas: cell and gene therapy, adaptive biology and advanced biotechnology. Our portfolio companies use biology to accelerate scientific breakthroughs that solve some of society's most challenging problems. Committed to this goal, Paragon and its partners have invested more than $1.4 billion in its portfolio companies since 2017. Learn more at https://paragonbiosci.com/.
SOURCE Evozyne, Inc.